Yuan Youhua, Xu Junhong, Chen Guohua, Liu Yan, Ouyang Libo, Ma Bing, Wang Baoya, Yan Wenjuan, Zhang Qi, Ma Qiong, Zhang Jiangfeng, Mao Xiaohuan, Zhang Xiaohuan, Geng Yiman, Wang Huiling, Li Yi, Zheng Peiming, Wang Rong
Department of Special Laboratory, Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, and People's Hospital of Henan University, Zhengzhou, 450003, Henan, People's Republic of China.
Department of Clinical Microbiology, Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, and People's Hospital of Henan University, Zhengzhou, 450003, Henan, People's Republic of China.
Sci Rep. 2025 May 22;15(1):17762. doi: 10.1038/s41598-025-02927-7.
The neutralisation ability of homologous and heterologous booster vaccinations against the KP.2 variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is unknown. Therefore, we aimed to evaluate the neutralisation of the Omicron variants by comparing serum samples from Chinese individuals who received heterologous boosters (from different manufacturers) with those who received homologous boosters (from the same manufacturer) against SARS-CoV-2. We collected serum samples from participants in the homologous (n = 38) and heterologous booster groups (n = 38) over 690 days. Serum pseudo virus neutralisation was tested against the prototype, XBB.1, JN.1, and KP.2 variants to detect neutralisation titres. An enzyme-linked immunosorbent assay was used to measure the total concentration of neutralising antibodies against the receptor binding domain of SARS-CoV-2. Neutralisation assays revealed 12.3-, 12.3-, and 11.4-fold reductions against JN.1, KP.2, and XBB.1 variants, respectively, compared with that against the prototype. However, no significant difference was observed in neutralising antibody titres among the JN.1, KP.2, and XBB.1 Omicron variants. Additionally, homologous boosters and men produced fewer neutralising antibodies compared to heterologous boosters and women. Thus, our results demonstrate that the Omicron variant KP.2 exhibits similar evasion properties to those observed in other variants.
针对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的KP.2变体，同源和异源加强疫苗接种的中和能力尚不清楚。因此，我们旨在通过比较接受异源加强针（来自不同制造商）和同源加强针（来自同一制造商）的中国个体的血清样本对SARS-CoV-2的中和情况，来评估奥密克戎变体的中和作用。我们在690天内收集了同源加强针组（n = 38）和异源加强针组（n = 38）参与者的血清样本。对血清假病毒针对原型、XBB.1、JN.1和KP.2变体进行中和测试，以检测中和滴度。采用酶联免疫吸附测定法测量针对SARS-CoV-2受体结合域的中和抗体总浓度。中和试验显示，与针对原型相比，针对JN.1、KP.2和XBB.1变体的中和作用分别降低了12.3倍、12.3倍和11.4倍。然而，在JN.1、KP.2和XBB.1奥密克戎变体之间，中和抗体滴度未观察到显著差异。此外，与异源加强针和女性相比，同源加强针和男性产生的中和抗体较少。因此，我们的结果表明，奥密克戎变体KP.2表现出与其他变体类似的逃逸特性。
